CRYSVITA (burosumab injection) CRYSVITA (burosumab injection)

The first and only treatment that addresses the underlying cause of x-linked hypophosphataemia (XLH)

Discover CRYSVITA and redefine the possibilities for your XLH patients.

Assistance in Gaining Access to Crysvita

UltraCare services are designed to help facilitate patient access to CRYSVITA treatment.

Enrolling in UltraCare may help you to:

  • Understand a patient's Insurance Coverage
  • Access patient resources in the Patient Support Programs

Download a CRYSVITA Patient Enrollment Form to start the enrollment process

Fill out the form with your patient and fax it to 1-833-592-2273 (CARE). Please note that a completed form is required for your enrollment.



For additional support, please call 1-833-388-5872 (U-LTRA).

LESS

Indication and clinical use

CRYSVITA (Burosumab Injection) is indicated for the treatment of X-linked hypophosphataemia (XLH) in adult and pediatric patients 1 year of age and older.

Treatment should be initiated and monitored by a health professional experienced in the management of patients with metabolic bone diseases.

Safety and efficacy in geriatric populations have not been established.

    Please see Product Monograph for safety information discussing:

  • Contraindications in patients who take oral phosphate and active vitamin D analogues, in patients with a serum phosphorus within or above the normal range for age, and in patients with severe renal impairment or end stage renal disease.
  • Relevant warnings and precautions about hyperphosphataemia and risk of ectopic mineralization, injection site reactions, vitamin D decrease, driving and operating machinery, hypersensitivity reactions, immunogenicity, monitoring and laboratory tests, fertility, and pregnancy and breast-feeding.

Please click here for the Product Monograph, which also includes important information relating to adverse reactions and dosing information that has not been discussed in the piece. The Product Monograph is also available by calling 1-833-388-5872.

Indication and clinical use

CRYSVITA (Burosumab Injection) is indicated for the treatment of X-linked hypophosphataemia (XLH) in adult and pediatric patients 1 year of age and older.

Treatment should be initiated and monitored by a health professional experienced in the management of patients with metabolic bone diseases.

Safety and efficacy in geriatric populations have not been established.

    Please see Product Monograph for safety information discussing:

  • Contraindications in patients who take oral phosphate and active vitamin D analogues, in patients with a serum phosphorus within or above the normal range for age, and in patients with severe renal impairment or end stage renal disease.
  • Relevant warnings and precautions about hyperphosphataemia and risk of ectopic mineralization, injection site reactions, vitamin D decrease, driving and operating machinery, hypersensitivity reactions, immunogenicity, monitoring and laboratory tests, fertility, and pregnancy and breast-feeding.

Please click here for the Product Monograph, which also includes important information relating to adverse reactions and dosing information that has not been discussed in the piece. The Product Monograph is also available by calling 1-833-388-5872.

For additional information and questions about medical information or medical affairs, please contact Ultragenyx Medical Affairs at 1-833-388-5872 (U-LTRA).